Home / LILRB2/CD85d/ILT4 / Human LILRB2/CD85d/ILT4 Antibody

Human LILRB2/CD85d/ILT4 Antibody

Catalog #: MAB2078
7 Citations Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
MAB2078
MAB2078-SP
Detection of LILRB2/CD85d/ILT4 in Human Blood Monocytes by Flow Cytometry.
2 Images
Product Details
Citations (7)
FAQs
Supplemental Products
Reviews
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human LILRB2/CD85d/ILT4 Antibody Summary

Species Reactivity
Human
Specificity
Detects human LILRB2/CD85d/ILT4 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) ILT1, rhILT2, rhILT3, rhILT6, rhILT7, rhILT11, rhLIR6 or rhLIR8 is observed.
Source
Monoclonal Mouse IgG2A Clone # 287219
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
Mouse myeloma cell line NS0-derived recombinant human LILRB2/CD85d/ILT4
Gly24-His458
Accession # ACT64556
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated
Purity
Protein A or G purified from hybridoma culture supernatant

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (Catalog # 2078-T4)
under non-reducing conditions only
Flow Cytometry
0.25 µg/106 cells
See below
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 
Neutralization
Measured by its ability to neutralize LILRB2/CD85d/ILT4-mediated adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line. The Neutralization Dose (ND50) is typically 0.2-0.8 µg/mL in the presence of 35 µg/mL Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Flow Cytometry Detection of LILRB2/CD85d/ILT4 antibody in Human Blood Monocytes antibody by Flow Cytometry. View Larger

Detection of LILRB2/CD85d/ILT4 in Human Blood Monocytes by Flow Cytometry. Human peripheral blood monocytes were stained with Mouse Anti-Human CD14 PE-conjugated Monoclonal Antibody (Catalog # FAB3832P) and either (A) Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078) or (B) Mouse IgG2AIsotype Control (Catalog # MAB003) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B).

Neutralization Cell Adhesion Mediated by LILRB2/CD85d/ILT4 and Neutralization by Human LILRB2/CD85d/ILT4 Antibody. View Larger

Cell Adhesion Mediated by LILRB2/CD85d/ILT4 and Neutralization by Human LILRB2/CD85d/ILT4 Antibody. Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (Catalog # 2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (35 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078). The ND50 is typically 0.2-0.8 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: LILRB2/CD85d/ILT4

The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR) (1‑3). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC) (4). Human ILT4 is produced as a 598 amino acid (aa) precursor including a 21 aa signal sequence, a 440 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 116 aa cytoplasmic domain. The ECD contains four Ig-like domains, and the cytoplasmic domain contains three immunoreceptor tyrosine-based inhibitory motifs (ITIM) (5). The ECD of human ILT4 shares 76% aa identity with chimpanzee ILT4 and 74%, 81%, 33%, 52%, 77%, 61%, and 64 % aa identity with human ILT1, 2, 3, 5, 6, 7, and 8, respectively. ILT4 binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules (5‑9). It competes with CD8 alpha for MHC I binding but does not compete with KIR2DL1 (7). Ligation of ILT4 induces Tyr phosphorylation within its cytoplasmic ITIMs, a requirement for association with SHP-1 (4, 6). Activation of ILT4 inhibits signaling through Fc gamma RI (4) and Fc epsilon RI (6) and causes DC to become tolerogenic by downregulation of costimulatory molecules (10, 11). ILT4 mediates tolerogenic DC-induced CD4+ T cell energy in vitro and in vivo (10‑12).

References
  1. Suciu-Foca, N. et al. (2005) Int. Immunopharmacol. 5:7. 
  2. Hofmeister, V. and E.H. Weiss (2003) Semin. Canc. Biol. 13:317. 
  3. Hunt, J.S. et al. (2005) FASEB J. 19:681. 
  4. Finger, N.A. et al. (1998) Eur. J. Immunol. 28:3423. 
  5. Borges, L. et al. (1997) J. Immunol. 159:5192. 
  6. Colonna, M. et al. (1998) J. Immunol. 160:3096. 
  7. Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. 100:8856.
  8. Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552.
  9. Allen, R.L. et al. (2001) J. Immunol. 167:5543.
  10. Chang, C.C. et al. (2002) Nat. Immunol. 3:237.
  11. Ristich, V. et al. (2005) Eur. J. Immunol. 35:1133.
  12. Manavalan, J.S. et al. (2003) Transpl. Immunol. 11:245.
Long Name
Leukocyte Immunoglobulin-like Receptor, Subfamily B (with TM and ITIM Domains), Member 5
Entrez Gene IDs
10288 (Human)
Alternate Names
CD85 antigen-like family member D; CD85d antigen; CD85d; Ig-like transcript 4; ILT4; ILT-4; ILT4CD85d; Immunoglobulin-like transcript 4; Leukocyte immunoglobulin-like receptor 2; leukocyte immunoglobulin-like receptor subfamily B member 2 soluble isoform; leukocyte immunoglobulin-like receptor subfamily B member 2; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains); LILRB2; LIR2; LIR2CD85D; LIR-2subfamily A (with TM domain), member 6; member 2; MIR10; MIR10LILRA6; Monocyte/macrophage immunoglobulin-like receptor 10

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human LILRB2/CD85d/ILT4 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

7 Citations: Showing 1 - 7
Filter your results:

Filter by:

  1. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation
    Authors: X Chen, A Gao, F Zhang, Z Yang, S Wang, Y Fang, J Li, J Wang, W Shi, L Wang, Y Zheng, Y Sun
    Theranostics, 2021-01-19;11(7):3392-3416.
    Species: Human
    Sample Types: Whole Cells, Whole Tissue
    Applications: ICC, IHC, Neutralization
  2. Functionalization-dependent effects of cellulose nanofibrils on tolerogenic mechanisms of human dendritic cells
    Authors: S Tomi?, N Ili?, V Kokol, A Gruden-Mov, D Mihajlovi?, M Beki?, L Sofroni?-M, M ?oli?, D Vu?evi?
    Int J Nanomedicine, 2018-10-31;13(0):6941-6960.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  3. HLA-B27 homodimers and free H chains are stronger ligands for leukocyte Ig-like receptor B2 than classical HLA class I.
    Authors: Giles J, Shaw J, Piper C, Wong-Baeza I, McHugh K, Ridley A, Li D, Lenart I, Antoniou AN, DiGleria K, Kuroki K, Maenaka K, Bowness P, Kollnberger S
    J. Immunol., 2012-05-16;188(12):6184-93.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  4. Identification of IDO-positive and IDO-negative human dendritic cells after activation by various proinflammatory stimuli.
    Authors: Von Bubnoff D, Scheler M, Wilms H, Fimmers R, Bieber T
    J. Immunol., 2011-05-04;186(12):6701-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  5. The inhibitory Fc gamma IIb receptor dampens TLR4-mediated immune responses and is selectively up-regulated on dendritic cells from rheumatoid arthritis patients with quiescent disease.
    Authors: Wenink MH, Santegoets KC, Roelofs MF, Huijbens R, Koenen HJ, van Beek R, Joosten I, Meyer-Wentrup F, Mathsson L, Ronnelid J, Adema GJ, Bonvini E, Koenig S, van den Berg WB, van Riel PL, Radstake TR
    J. Immunol., 2009-09-04;183(7):4509-20.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  6. A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells.
    Authors: Lichterfeld M, Kavanagh DG, Williams KL, Moza B, Mui SK, Miura T, Sivamurthy R, Allgaier R, Pereyra F, Trocha A, Feeney M, Gandhi RT, Rosenberg ES, Altfeld M, Allen TM, Allen R, Walker BD, Sundberg EJ, Yu XG
    J. Exp. Med., 2007-11-19;204(12):2813-24.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  7. Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation.
    Authors: Masuda A, Nakamura A, Maeda T, Sakamoto Y, Takai T
    J. Exp. Med., 2007-04-09;204(4):907-20.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human LILRB2/CD85d/ILT4 Antibody

There are currently no reviews for this product. Be the first to review Human LILRB2/CD85d/ILT4 Antibody and earn rewards!

Have you used Human LILRB2/CD85d/ILT4 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review